Progress with Treatments for Alzheimer’s Disease

An estimated 50 million people worldwide have dementia, mostly due to Alzheimer’s disease. The inexorable progression of Alzheimer’s disease exerts a huge toll on patients, families, and society, costing approximately $1 trillion annually, an amount that is likely to increase with the growing number of elderly people. It is no surprise that Alzheimer’s disease is among the most feared diseases of aging. Hence, there is widespread interest as new clinical trial results are reported, but also much angst given all the trial failures to date. This issue of the Journal provides some tentative hope with the results of TRAILBLAZER-ALZ, a . . .